Structure Therapeutics (GPCR) to Release Earnings on Friday

Structure Therapeutics (NASDAQ:GPCR) is projected to post its quarterly earnings results before the market opens on Friday, March 14th. Analysts expect Structure Therapeutics to post earnings of ($0.23) per share for the quarter.

Structure Therapeutics (NASDAQ:GPCR) last issued its quarterly earnings data on Thursday, February 27th. The company reported ($0.22) EPS for the quarter, topping the consensus estimate of ($0.23) by $0.01. On average, analysts expect Structure Therapeutics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Structure Therapeutics Stock Performance

NASDAQ:GPCR opened at $20.53 on Wednesday. The stock has a 50-day simple moving average of $25.72 and a two-hundred day simple moving average of $32.74. Structure Therapeutics has a 52-week low of $19.39 and a 52-week high of $62.74. The firm has a market capitalization of $1.18 billion, a PE ratio of -27.74 and a beta of -2.35.

Wall Street Analysts Forecast Growth

GPCR has been the subject of several recent research reports. Stifel Nicolaus initiated coverage on Structure Therapeutics in a report on Wednesday, January 8th. They set a “buy” rating and a $50.00 price target for the company. HC Wainwright reissued a “buy” rating and set a $80.00 price target on shares of Structure Therapeutics in a report on Thursday, December 19th. William Blair initiated coverage on Structure Therapeutics in a report on Friday, February 28th. They set an “outperform” rating for the company. Finally, JMP Securities reissued a “market outperform” rating and set a $91.00 price target on shares of Structure Therapeutics in a report on Wednesday, December 18th. Eight equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, Structure Therapeutics presently has a consensus rating of “Buy” and an average target price of $81.29.

Structure Therapeutics Company Profile

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company’s lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.